| abstract |
Disclosed are novel pyrimidopyrazole compounds as fourth generation (T790M/C797S mutation) EGFR kinase inhibitors and pharmaceutical use thereof, specifically disclosed are a compound represented by formula (I), a stereoisomer, a racemate, a tautomer, an isotope label, a nitrogen oxide or a pharmaceutically acceptable salt thereof. Said compounds have good efficacy in treating diseases caused by abnormal mutation of EGFR Del19/T790M/C797S and L858R/T790M/C797S. |